CURRICULUM VITAE

Name: Robert Bendesky

Position: Supervisor, Tech Ops

Education: University of Pittsburgh, B.S.

Professional Experience:

Charles River Laboratories, Horsham, PA

Supervisor, Tech Ops, March 2019 to present. Supervise members of the Technical Operations group including: management and training of personnel, participation in interdepartmental and intradepartmental projects and point of contact in matters pertaining to operation of the laboratory. Responsible for managing the technical staff in assigned area to ensure compliance with the protocol and applicable SOPs and maintain the raw data for non-clinical studies. Ensure compliance with all applicable regulations and with site and departmental policies, practices and procedures.

Invivotek, LLC

Preclinical Research Associate, 2017 – March 2019. Plan, optimize, and perform in-vivo and in-vitro assays. Specialize in small animal models for drug discovery in Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. In-vitro Imaging System (IVIS Spectrum) of mice to chart tumor growth by ROI and assigned-color spectrum. Use of SARRP [Small Animal Radiation Research Platform] to target radiation to pre-clinical animal models. Execute novel compound efficacy studies in various animal models of disease and PK/ PD Studies

Melior Discovery

Senior Research Associate, 2012 to 2017. CNS research, specializing in Electroencephalography and Electromyography experiments in rats and mice, including surgical implantation of electrodes, configuration of EEG recording equipment, dosing and running experiment and initial analysis of results. Measured electro myocardial deficits in SOD mice, showed deficiencies in motor action potentials before behavioral deficits became noticeable. Performed 6-OHDA chemical lesioning of rat brains for dopamine-related assays. Ran a variety of behavioral studies, necropsy dissections, tissue preparation.

TEVA / CEPHALON

Research Associate VI, 2004 – 2011.

Neurobiology department: Characterized novel H3 antagonists using the rat dipsogenia and the social recognition behavioral models leading

to the nomination of a novel H3 antagonist to preclinical development. Discovered novel antinociceptive agents utilizing the Hargreaves apparatus (thermal sensitivity), plethysmometer (paw edema), and von Frey filaments (tactile sensitivity). Designed and ran PTZ-induced seizure tests to determine effectiveness of anti-convulsive activity of novel compounds.

Oncology Department: Cultured various cancer cell lines for xenograft implants into SCID and Nu/Nu mice, dosed with test compounds and measured tumor growth and regression for anti-tumor efficacy studies and PK/PD analysis. Ran Western Blots on lysates of collected tumors to determine pharmacodynamic activity of test compounds. Projects included FAK, ALK (lymphoma or leukemia) and AXL (breast and lung cancer) inhibitor discovery, resulting in one clinical development candidate.

National Disease Research Interchange

Human Biological Data Interchange Coordinator, 2003 to 2004. Administered the nation's largest database of Type I Diabetes families (6500+ individuals).

GlaxoSmithKline

Sr. Scientist - Musculoskeletal Department, 2002 to 2003. Performed aseptic rodent surgery; implanted arterial catheters into rat femoral artery. Developed and ran 4x4 and 6x2 Latin Square studies. Collected whole blood samples, determined post-treatment Ca++ blood levels.

MERCK & COMPANY, INC.

Sr. Research Biologist - Department of Neuroscience, 1980 – 2002. Worked in Neuropharmacology, Cardiovascular, Gastroenterology, and New Lead Pharmacology departments. Gathered information on target medical conditions, modified existing techniques and created new protocols to suit the current research focus. Characterized anti-hypertensive activities of the novel Angiotensin II receptor antagonist Losartan (Cozaar®).

“An Equal Opportunity Employer, M/F/Disabled/Veteran”

v – 19-Nov-2018